Blood Podcast Review Series on Acute Lymphoblastic Leukemia (ALL)
Sep 18, 2025
Dr. Mark Litzow, a leading hematology professor from the Mayo Clinic, discusses groundbreaking immunotherapy advancements for Acute Lymphoblastic Leukemia (ALL). He highlights the impressive clinical trial results of treatments like blinatumomab and inotuzumab, boasting high remission rates and improved survival, especially among older patients. The conversation emphasizes the shift towards personalized, less toxic therapies, aiming to enhance patient outcomes and reduce chemotherapy intensity. This innovative approach could revolutionize ALL treatment, offering renewed hope for many.
AI Snips
Chapters
Transcript
Episode notes
Immunotherapy Is Changing Frontline ALL Care
- Blinatumomab and inotuzumab are reshaping frontline B‑cell ALL treatment by enabling high remission and MRD‑negative rates.
- Trials show immunotherapy can reduce chemotherapy intensity while improving survival outcomes.
Use Blinatumomab In Consolidation For MRD‑Negativity
- Use blinatumomab in consolidation for adults who achieve MRD negativity to improve long‑term survival.
- Prefer the four‑cycle approach used in ECOG when following the trial evidence for adults aged 30–70.
Elderly Patients Achieve High Remission With Inotuzumab
- The Alliance trial gave inotuzumab induction without systemic chemotherapy to patients over 65 and saw over 90% CR and ~80% one‑year survival.
- This example suggests older patients may avoid intensive chemo using immunotherapy‑first approaches.